ストックスクリーナーアプリを入手
4.395
0.80%
0.045
前日終値:
$4.35
開ける：
$4.36
24時間の取引高:
69,288
Relative Volume:
0.03
時価総額：
$869.17M
収益：
$14.08M
当期純損益:
$-33.50M
株価収益率:
-25.06
EPS:
-0.1754
ネットキャッシュフロー:
$-39.72M
1週間 パフォーマンス:
+4.40%
1か月 パフォーマンス:
+4.40%
6か月 パフォーマンス:
-0.57%
1年 パフォーマンス:
+36.18%
1日の値動き範囲:
$4.342
$4.415
1週間の範囲:
$4.19
$4.53
52週間の値動き範囲:
$3.04
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.40 | 859.29M | 14.08M | -33.50M | -39.72M | -0.1754 |
VRTX
Vertex Pharmaceuticals Inc
|
437.29 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
639.93 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.14 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.40 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.27 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-02 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | 開始されました | Jefferies | Hold |
| 2020-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
| 2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
| 2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
| 2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 繰り返されました | Wedbush | Outperform |
| 2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
Arbutus Posts Profit After Moderna Patent Settlement - MyChesCo
ABUS Stock Price, Quote & Chart | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake - Stock Titan
Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies - Minichart
Arbutus Biopharma Corporation 8-K Filing: Company Details, Financial Data, and NASDAQ Listing (May 2026) - Minichart
Is Arbutus Biopharma (ABUS) Overvalued After Q1 2026 Earnings Be - GuruFocus
Arbutus Biopharma (ABUS) Reports Strong Q1 Earnings with $0.87 E - GuruFocus
Arbutus Biopharma Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Arbutus Biopharma earnings beat by $0.91, revenue topped estimates - Investing.com
Arbutus Biopharma Corp 1Q 2026: Revenue $179.13M, EPS $0.87— 10-Q Summary - TradingView
Arbutus: Q1 Earnings Snapshot - 10TV
Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit - Stock Titan
Arbutus (NASDAQ: ABUS) swings to Q1 profit on $179M revenue surge - Stock Titan
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - Stock Titan
Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS) - Seeking Alpha
MSN Money - MSN
Arbutus Biopharma Corporation (ABUS) Stock Analysis: Exploring a 20% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
5 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
Whitefort lifts Arbutus (ABUS) economic stake to 9.8% - Stock Titan
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran - Insider Monkey
Arbutus Drug Candidate Receives FDA Fast Track Designation - MyChesCo
ABUS (Arbutus Biopharma) Other Liabilities for Banks - GuruFocus
FDA grants Arbutus Biopharma drug fast track designation - Pennsylvania Business Report -
Arbutus (ABUS) Stock: Stability Assessment (Momentum Fading) 2026-04-20Trending Momentum Stocks - newser.com
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Insider Monkey
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Whitefort Capital Management, LP Increases Stake in Arbutus Biop - GuruFocus
Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Arbutus Biopharma (ABUS) Receives FDA Fast Track Designation for Imdusiran - GuruFocus
Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed - Quiver Quantitative
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseHere's Why - MarketBeat
Arbutus Biopharma Corporation Files Form 8-K with SEC – Company Details, Address, and NASDAQ Listing Information 24252675 - Minichart
ABUS Receives Fast Track Designation from FDA for Imdusiran - GuruFocus
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - The Manila Times
[8-K] Arbutus Biopharma Corp Reports Material Event - Stock Titan
Arbutus Biopharma (ABUS) 2026 proxy adds 16.3M-share incentive plan vote - Stock Titan
Whitefort outlines 8.1% Arbutus Biopharma (ABUS) stake in amended 13D - Stock Titan
ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Arbutus reports results, announces $2.25B Moderna settlement - MSN
ABUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):